2.05 -0.04 (-1.91%)
NVAX
Stock Details
Last Trade:2.05 Change:-0.04 (-1.91%) Prev Close:2.09 Open: 2.09 Days Range:1.99 – 2.14 52 Week Range: 0.52 - 7.79 Volume:1075079 P/E: N/AEPS:-0.42
View AllRecent Alerts 02/09/10
Recent Alert on 02/08/10 at 12:28pm
Unusual 11 Mid-Day Movers 2/8: IIG, CFSG, PNX, HAS Higher; CTIC, SHIP, NVAX, NBG Lower
Unusual 11 Mid-Day Movers 2/8: IIG, CFSG, PNX, HAS Higher; CTIC, SHIP, NVAX, NBG Lower
Cell Therapeutics, Inc. (Nasdaq: CTIC) 27.4% LOWER; shares are under pressure Monday following documents from the FDA showing that reviewers questioned the effectiveness of the company's experimental lymphoma drug, pixantrone. The FDA reviewers also... Read More
Recent Alert on 02/08/10 at 10:36am
Morning Movers 2/8: CFSG, IIG, LFUS, BBEP Higher; CAGC, CTIC, TONE, SHIP Lower
Morning Movers 2/8: CFSG, IIG, LFUS, BBEP Higher; CAGC, CTIC, TONE, SHIP Lower
Recent Alert on 02/08/10 at 7:24am
Novavax (NVAX) to Cease Negotiations with ROVI Pharma for Drug Collaboration
Novavax (NVAX) to Cease Negotiations with ROVI Pharma for Drug Collaboration
Recent Alert on 01/12/10 at 8:27am
Novavax (NVAX) Reports Positive Results from RSV Vaccine Pre-Clinical
Novavax (NVAX) Reports Positive Results from RSV Vaccine Pre-Clinical
Recent Alert on 01/12/10 at 8:27am
Novavax (NVAX) Reports Positive Results from RSV Vaccine Pre-Clinical
Novavax (NVAX) Reports Positive Results from RSV Vaccine Pre-Clinical
View AllRecent Press Releases
Press Release on 02/08/10 at 12:41pm
NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
Press Release on 02/08/10 at 10:30am
NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
Press Release on 02/08/10 at 2:00am
Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
Press Release on 02/05/10 at 8:00am
NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
View AllRecent SEC Filings
SEC Filing on 02/09/10 at 2:33pm
Form SC 13G/A NOVAVAX INC Filed by: IRONWOOD INVESTMENT MANAGEMENT LLC
Form SC 13G/A NOVAVAX INC Filed by: IRONWOOD INVESTMENT MANAGEMENT LLC
View AllRecent Blog Posts
Blog Posts on 11/05/09 at 11:40am
Analyst upgrades, downgrades and initiations: CMCSA, GAME, GRMN, ETN, FO, MDT, MSO ...
Analyst upgrades, downgrades and initiations: CMCSA, GAME, GRMN, ETN, FO, MDT, MSO ...
the winner?
10/30/09 at 6:22am by lucai think that nvax , it's the natural winner of the emergency situation of flu vaccine: will have a emergency approve by FDA?